• Je něco špatně v tomto záznamu ?

Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome

PL. Antignani, C. Allegra, J. Fareed,

. 2019 ; 38 (1) : 17-21. [pub] 20181120

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19034890

BACKGROUND: The study was initiated following the observation of complete recanalization of thrombus in subjects with DVT treated with rivaroxaban after 1-2 weeks. The aim of this observational retrospective study was to evaluate clinically and by means of echo color Duplex, the fibrinolytic effect of rivaroxaban in patients with recent and previous DVT. To accomplish this two populations of patients were evaluated. METHODS: Group 1 was comprised of 31 patients (ranging in age 52-73 years) with popliteal-femoral DVT (12 months ago) treated with standard anticoagulant therapy. In these patients, we found a complete superficial femoral recanalization and partial recanalization of the popliteal vein (30% of residual thrombus). The patients had normal creatinine clearance and liver function. The patients were switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy. Group 2 was comprised of 22 patients (ranging in age 65-82 years) with previous popliteal-femoral DVT and documented complete common femoral veins recanalization who presented with a recent superficial femoral vein re-thrombosis (1 week before). The patients had normal creatinine clearance and liver function. The patients switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy. RESULTS: In group 1, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks of rivaroxaban therapy. In group 2, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks, and the complete recanalization of the acute re-thrombosis of the superficial femoral veins after 2 weeks of rivaroxaban therapy. No adverse events for both groups were observed. CONCLUSIONS: Our results suggest that rivaroxaban could have a pro-fibrinolytic effect not only on recent thrombus but also on organized thrombus that results in a complete recanalization of affected veins. It is proposed that this lytic effect will preserve venous valve structure and lead to a reduction of incidence of post-thrombotic syndrome in rivaroxaban treated patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19034890
003      
CZ-PrNML
005      
20191014114745.0
007      
ta
008      
191007s2019 it f 000 0|eng||
009      
AR
024    7_
$a 10.23736/S0392-9590.18.04031-2 $2 doi
035    __
$a (PubMed)30465419
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Antignani, Pier Luigi $u Vascular Center, Nuova Villa Claudia, Rome, Italy - antignanipl@gmail.com.
245    10
$a Treatment of deep vein thrombosis with rivaroxaban and its potential to prevent the post-thrombotic syndrome / $c PL. Antignani, C. Allegra, J. Fareed,
520    9_
$a BACKGROUND: The study was initiated following the observation of complete recanalization of thrombus in subjects with DVT treated with rivaroxaban after 1-2 weeks. The aim of this observational retrospective study was to evaluate clinically and by means of echo color Duplex, the fibrinolytic effect of rivaroxaban in patients with recent and previous DVT. To accomplish this two populations of patients were evaluated. METHODS: Group 1 was comprised of 31 patients (ranging in age 52-73 years) with popliteal-femoral DVT (12 months ago) treated with standard anticoagulant therapy. In these patients, we found a complete superficial femoral recanalization and partial recanalization of the popliteal vein (30% of residual thrombus). The patients had normal creatinine clearance and liver function. The patients were switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy. Group 2 was comprised of 22 patients (ranging in age 65-82 years) with previous popliteal-femoral DVT and documented complete common femoral veins recanalization who presented with a recent superficial femoral vein re-thrombosis (1 week before). The patients had normal creatinine clearance and liver function. The patients switched from warfarin to rivaroxaban due to a lack of compliance with warfarin therapy. RESULTS: In group 1, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks of rivaroxaban therapy. In group 2, all patients exhibited the complete recanalization of the popliteal veins after 4 weeks, and the complete recanalization of the acute re-thrombosis of the superficial femoral veins after 2 weeks of rivaroxaban therapy. No adverse events for both groups were observed. CONCLUSIONS: Our results suggest that rivaroxaban could have a pro-fibrinolytic effect not only on recent thrombus but also on organized thrombus that results in a complete recanalization of affected veins. It is proposed that this lytic effect will preserve venous valve structure and lead to a reduction of incidence of post-thrombotic syndrome in rivaroxaban treated patients.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a inhibitory faktoru Xa $x terapeutické užití $7 D065427
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a vena femoralis $x diagnostické zobrazování $7 D005268
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a vena poplitea $x diagnostické zobrazování $7 D011152
650    _2
$a posttrombotický syndrom $x prevence a kontrola $7 D054070
650    _2
$a rivaroxaban $x terapeutické užití $7 D000069552
650    _2
$a trombolytická terapie $7 D015912
650    _2
$a výsledek terapie $7 D016896
650    _2
$a duplexní dopplerovská ultrasonografie $7 D018616
650    _2
$a žilní trombóza $x diagnostické zobrazování $x farmakoterapie $7 D020246
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Allegra, Claudio $u Central European Vascular Forum, Praha, Czech Republic.
700    1_
$a Fareed, Jawed $u Hemostasis and Thrombosis Research Laboratories, Loyola University Medical Center, Maywood, IL, USA.
773    0_
$w MED00002267 $t International angiology : a journal of the International Union of Angiology $x 1827-1839 $g Roč. 38, č. 1 (2019), s. 17-21
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30465419 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20191014115209 $b ABA008
999    __
$a ok $b bmc $g 1451550 $s 1073440
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 38 $c 1 $d 17-21 $e 20181120 $i 1827-1839 $m International angiology $n Int Angiol $x MED00002267
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...